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Background: Understanding immunogenicity and safety of monovalent type 2 oral poliovirus vaccine (mOPV2) in inactivated 
poliovirus vaccine (IPV)–immunized children is of major importance in informing global policy to control circulating vaccine-
derived poliovirus outbreaks.
Methods: In this open-label, phase 4 study (NCT02582255) in 100 IPV-vaccinated Lithuanian 1–5-year-olds, we measured 
humoral and intestinal type 2 polio neutralizing antibodies before and 28 days after 1 or 2 mOPV2 doses given 28 days apart and 
measured stool viral shedding after each dose. Parents recorded solicited adverse events (AEs) for 7 days after each dose and unso-
licited AEs for 6 weeks after vaccination.
Results: After 1 mOPV2 challenge, the type 2 seroprotection rate increased from 98% to 100%. Approximately 28 days after 
mOPV2 challenge 34 of 68 children (50%; 95% confidence interval, 38%–62%) were shedding virus; 9 of 37 (24%; 12%–41%) were 
shedding 28 days after a second challenge. Before challenge, type 2 intestinal immunity was undetectable in IPV-primed children, 
but 28 of 87 (32%) had intestinal neutralizing titers ≥32 after 1 mOPV2 dose. No vaccine-related serious or severe AEs were reported.
Conclusions: High viral excretion after mOPV2 among exclusively IPV-vaccinated children was substantially lower after a sub-
sequent dose, indicating induction of intestinal immunity against type 2 poliovirus.
Keywords.  poliovirus; vaccine; inactivated poliovirus vaccine; oral poliovirus vaccine; viral shedding; immunogenicity.
Poliomyelitis is on the verge of global eradication, with only 
Pakistan and Afghanistan currently reporting wild poliovirus 
type 1 cases [1]. Eradication of wild-type 2 poliovirus was de-
clared on 20 September 2015 [2], and eradication of wild-type 3 
poliovirus on 24 October 2019 [3]. However, in rare cases oral 
poliovirus vaccine (OPV) viruses can revert to neurovirulence 
and cause vaccine-associated paralytic poliomyelitis in 
vaccinees or susceptible contacts. In settings with low immuni-
zation coverage, shed vaccine virus can acquire transmissibility 
and neurovirulence to generate vaccine-derived polioviruses 
(VDPVs). The OPV type 2 component has been associated with 
>90% of all circulating VDPVs (cVDPVs) globally [4]. To miti-
gate against cVDPV and vaccine-associated paralytic poliomy-
elitis, type 2–containing OPV was withdrawn from routine use 
and replaced with bivalent OPV containing only types 1 and 
3 in May 2016 [5]. This unprecedented globally synchronized 
switch is the first step toward a sequential withdrawal of all live 
poliovirus vaccines and replacement by inactivated poliovirus 
vaccine (IPV) as vaccine of choice for elective polio protection 
after certification of eradication of wild polioviruses [6].
OPV replicates in the gut and induces primary intestinal im-
munity, an essential factor to control person-to-person trans-
mission in settings of poor hygiene [7]. IPV induces humoral 
immunity that provides protection against paralytic poliomy-
elitis, but limited primary intestinal immunity compared with 
OPV [8]. Therefore, global IPV-only primary immunization 
regimens in the postcertification period will eliminate the risk 
of generating VDPV but will not affect person-to-person viral 
transmission in settings with cVDPV. This situation is illustrated 
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by the ongoing, expanding type 2 cVDPV outbreaks in multiple 
countries in Africa and elsewhere for over 4 years after type 2 
OPV (OPV2) cessation [4]. For this reason, stockpiles of mon-
ovalent OPV (mOPV) must be maintained for outbreak con-
trol, for which novel, more genetically stable OPV vaccines are 
being developed [9]. We conducted the current study knowing 
that the data generated would be valuable for interpreting other 
studies with these new vaccines, as understanding the dynamics 
of mOPV challenge in young children with no prior OPV ex-
posure will be critical for designing the outbreak response strat-
egies and preparing contingency options for the global program.
Before OPV2 cessation, the Lithuanian primary immuni-
zation schedule, 3 IPV doses administered in the first year 
of life, provided a unique opportunity to assess primary im-
munogenicity from an IPV-only regimen in conditions that 
mimic the posteradication era. We assessed humoral and in-
testinal immunity before and after 1 or 2 challenge doses of 
type 2 mOPV (mOPV2) in 1–5-year-old Lithuanian children, 
along with assessment of postvaccination viral shedding 
dynamics.
METHODS
This open-label, phase 4 study was conducted between 7 
January 2016 and 12 May 2016 in 3 outpatient clinics located in 
Lithuania: Centro Poliklinika and Naujininku Poliklinika, both 
in Vilnius, and UAB Inmedica in Kaunas. The protocol was ap-
proved by the local institutional review board and registered on 
ClinicalTrials.gov (NCT02582255). The study was performed 
according to current International Council for Harmonisation 
and Good Clinical Practice guidelines. Coprimary objectives 
were to assess safety, as occurrence of severe adverse events 
(AEs), serious AEs (SAEs), and important medical events 
(IMEs) related to the vaccination, and humoral immunoge-
nicity, as the type 2 seroprotection rate 28 days after the first 
mOPV2 dose. Secondary objectives included assessment of all 
SAEs or IMEs and any solicited or unsolicited AEs throughout 
the study, and humoral immunogenicity to all 3 poliovirus 
types at 7 and 28 days after each vaccination. An exploratory 
objective was assessment of viral shedding, later augmented 
with an evaluation of intestinal immunity at baseline and after 
each dose.
Participants
Eligible participants were 1–5-year-old children with a docu-
mented history of at least 3 IPV vaccinations in their first year 
of life, healthy with no obvious medical conditions on ex-
amination at enrollment, and with no poliovirus vaccination 
within the previous 3 months or any other vaccination within 
the previous 4 weeks. Other exclusion criteria included any 
known allergy to a vaccine component, any known immu-
nodeficiency or chronic illness, and the presence of anyone 
in the participant’s household who had received OPV in the 
previous 3 months.
Vaccine
The mOPV2 challenge vaccine, Polio Sabin Mono Two (oral) 
(GlaxoSmithKline Biologicals; lot DOP2A004AZ) is a World 
Health Organization (WHO)–prequalified, monovalent, live 
attenuated polio virus vaccine of the Sabin strain type 2 (P712, 
Ch, 2ab), propagated in MRC5 human diploid cells. Each 
0.1-mL dose, delivered as 2 drops from a supplied polyeth-
ylene dropper, contained ≥105 50% cell culture infective dose 
(CCID50) of type 2 poliovirus, magnesium chloride as stabilizer, 
and trace amounts of neomycin sulfate and polymyxin B sulfate.
Procedures
Enrolled children were randomized (1:1) to receive 1 dose of 
mOPV2 or 2 doses, 4 weeks apart. Parents or guardians used 
mobile phones and remote data entry to record solicited sys-
temic AEs for 7 days after each vaccination, and any unsolicited 
AEs, including SAEs and IMEs occurring throughout the study 
duration up to 6 weeks after the final dose of mOPV2. Parents/
guardians also supplied weekly stool samples for assessment of 
viral shedding by real-time reverse-transcription polymerase 
chain reaction (RT-PCR) [10], augmented with an assessment 
of intestinal immunity at baseline and after each dose as de-
scribed elsewhere [11].
Viral Shedding and Humoral and Intestinal Immunity
Type 2 neutralizing antibodies (NAbs) were measured in serum 
samples collected before the first dose and 28 days after each 
vaccination using the WHO standard microneutralization assay 
(WHO EPI GEN 93.9) at the laboratories of Centers for Disease 
Control and Prevention in Atlanta, Georgia, as described else-
where [12]. The application of the assay used there has a lower 
limit of quantitation (LLOQ) of 2.5 log2 titer and an upper limit 
of quantitation (ULOQ) of 10.5 log2 titer. Antibody titers are re-
ported as the reciprocal of the dilution, equating to a range from 
5.7 (LLOQ) to 1448 (ULOQ). Geometric mean titers (GMTs) 
were calculated using the antilog of the arithmetic mean of 
log2 antibody titers with LLOQ and ULOQ as observed values, 
wherever these values were observed.
After extraction of nucleic acid from stool samples collected 
at days 0–10, 7, 14, 21, and 28 in groups 1 and 2, and at days 35, 
42, and 56 in group 2, poliovirus was detected using RT-PCR 
[13]. If detected, the titer was measured as CCID50.
Intestinal type 2 poliovirus–specific neutralizing activity was 
measured at Dartmouth University in the same stool samples 
by limiting dilution inhibition of a luciferase-expressing type 
2–specific wild-type–derived polio pseudovirus in vitro, ex-
pressed as the titer needed to achieve 60% neutralization, as de-
scribed elsewhere [14]. Titers <4 were considered undetectable 
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and recorded as 2.  Total and poliovirus type 2–specific con-
centrations of immunoglobulin A  (IgA) in stool specimens 
were assessed relative to a serum standard, using a multiplex 
Luminex-based microsphere assay developed by coupling mon-
ovalent IPVs to fluorescently-coded magnetic microspheres 
[15], with relative concentration units below the limit of detec-
tion (≤10) reported as 5.
Statistical Analysis
There were 2 coprimary end points—safety and day 28 
seroprotection rate—on which the sample size was based. 
For safety evaluation, a sample size of 45 evaluable partici-
pants provided 90% probability of observing ≥1 unexpected 
AE with true rate of 5%, which was boosted to 50 to allow for 
10% dropout before final safety evaluation. For the immunoge-
nicity end point, we assumed a seroprotection rate after a single 
dose of type 2 OPV in this population of 97%. Recognizing 
that these data may provide a historical control comparator 
for development of novel type 2 vaccines, 48 evaluable parti-
cipants per group would provide 80% power for a hypothetical 
noninferiority comparison of a new vaccine with these data 
with type I error rate α = 0.025, and noninferiority margin 10%. 
Because the safety end point required 50 participants per group, 
and all 1- and 2-dose participants contribute to the immunoge-
nicity end point, 100 participants were to be enrolled.
Immunogenicity was expressed as seroprotection rate and 
NAb GMT before and 28  days after each vaccination, and as 
type 2 seroconversion rates 28  days after each vaccination. 
Seroprotection rates were defined as group percentages with an 
NAb titer ≥8. Seroconversion was defined as a change from se-
ronegative to seropositive with a NAb titer ≥8, or in baseline 
seropositive children, a ≥4-fold increase in antibody titer over 
baseline. A stool viral shedding index end point (SIE) was cal-
culated as the average of log10 CCID50 per gram determined 
using real time RT-PCR (viral identity) and CCID50 (titer) from 
samples obtained on days 7, 14, 21, and 28 after each vaccine 
dose, and this was summarized descriptively. The per-protocol 
population, defined as those without major protocol deviations 
potentially interfering with immunogenicity assessments, was 
the primary population for analysis.
Pairwise correlations between mOPV2 viral shedding, 
type 2–specific stool NAb titers, and type 2–specific IgA 
levels 2 weeks after the first mOPV2 dose were estimated 
using Spearman rank correlation coefficients. For evaluation 
of intestinal antibody responses, responders were defined as 
those achieving a poliovirus type 2–specific stool NAb titer 
≥32, and high shedders as those who shed mOPV2 virus 
with a titer ≥8.25 log10 CCID50 per gram, the ULOQ. The 
odds of being a high shedder (ie, shedding vaccine virus at 
the ULOQ) after the second challenge dose, given the shed-
ding status after the first challenge dose, were estimated 
using logistic regression.
Poliovirus type 2–specific stool neutralization and IgA levels 
are summarized on day 0 and after mOPV2 challenge as an ag-
gregate of values obtained ±2 days of each target day, presented 
as a single value representing the mean of the log10 CCID50 
levels or the geometric means of the type 2–specific stool neu-
tralization or IgA if ≥2 stool samples were collected within each 
5-day window. Viral shedding titers and poliovirus type 2–spe-
cific stool neutralization titers and IgA concentrations were 
plotted by day after mOPV2 challenge. Intestinal responses 
were summarized for days 0, 7, 14, 21, and 28 days after the first 
and second mOPV2 challenges by whether individuals were (1) 
responders or nonresponders and (2) high shedders or not after 
the first challenge dose. Distributions across categories were 
compared using the Mann-Whitney U test. All P values are 
from 2-sided statistical tests, and all analyses were performed 




Of 101 participants screened, 100 were enrolled into the 2 
groups (Figure 1). The mean age was 3.0 years (Table 1), and 
female-male distribution was 45:55. Most children (82%) had 
received ≥4 prior IPV doses administered in the nationally re-
commended diphtheria and tetanus toxoids and acellular per-
tussis–IPV–hepatitis B virus/Haemophilus influenzae type b 
vaccine combination, with 79% having received their most re-
cent vaccination ≥1 year previously. Three children in group 2 
did not receive their second mOPV2 so were excluded from the 
per-protocol population, but all other participants completed 
all visits according to protocol.
Safety and Tolerability
Safety assessments in 100 children for the first dose and in 47 
for the second showed that the mOPV2 challenge was well toler-
ated (Table 2). One SAE, bronchitis, was observed 21 days after 
the first dose, resolved after 11  days, and was considered in-
consistent with a causal association to immunization. No SAEs, 
IMEs, or severe AEs were observed with any participant. There 
were few solicited AEs, which were all mild and inconsistent 
with causal association to immunization. All unsolicited AEs 
were reported as mild or moderate and inconsistent with causal 
association to vaccination, and none led to the withdrawal of a 
child from the study.
Humoral Immunogenicity
Humoral immunogenicity assessments were made in 96 children 
before and after the dose 1, and in 47 after dose 2. These showed 
a high level of humoral immunity to all 3 polioviruses at base-
line, with seroprotection rates of 97%, 98%, and 96% to types 1, 
2 and 3, respectively (Table 3). Against this high background, 
little change could be observed in the seroprotection rates after 
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1 or 2 doses of mOPV2, although there were some cases of se-
roconversion in those whose baseline titers were sufficiently 
below the ULOQ to be evaluable. Seroconversion against type 
2 was observed in 29 of 41 evaluable participants (71%) 28 days 
after 1 dose. No further increase was observed after 2 doses 
when 11 of 17 evaluable participants (65%) still displayed se-
roconversion (Table 3). Surprisingly, 9 of 29 (31%) and 3 of 31 
(10%) displayed seroconversion to types 1 and 3, respectively, 
7 days after 1 dose of mOPV2, suggesting some heterotypic im-
mune response occurred.
These observations were reflected in the serum NAb GMTs 
(Figure  2), which were relatively constant for NAbs to types 
1 and 3 from day 0 to days 28 and 56, after 1 and 2 mOPV2 
doses, also reflecting the frequency of subjects with humoral 
immunity near the assay ULOQ. Within the limitations of the 
high baseline, there was evidence of an increase in the type 2 
NAb GMT at day 28, with no further increase observed after a 
second dose of mOPV2. Median log2 serum type 2 Nab titers 
rose from 9.0 (95% confidence interval [CI], 8.2–9.8) to 10.2 
(10.2 to ≥10.5) after 1 dose, and from 9.2 (7.5–9.8) to ≥10.5 (9.8 
to ≥10.5) among children receiving 2 doses. 
Viral Shedding
After a single dose, 92% of the 92 evaluable participants had de-
tectable virus (PCR positive) in their stool samples 7 days later, 
a proportion that declined to 89%, 67%, and 50% on days 14, 
21, and 28, respectively (Figure 3). On day 28, there was a me-
dian value of 4.83 log10 CCID50/g (95% CI, 3.69 to ≥8.25) for 
virus in stool samples from shedders, with 1.38 log10 CCID50/g 
(.00–3.19) across all subjects submitting samples at this time 
point (Table 4). One week after the second dose, 45% of the 44 
evaluable participants were shedding vaccine virus, a propor-
tion that declined to 24% (95% CI, 12%–41%) 4 weeks after the 
second dose with a median value of 3.16 log10 CCID50/g (95% 
CI, 2.78 to ≥8.25) among shedders.
The median viral SIE values in all analyzed participants were 
4.03 after dose 1 and 0.69 after dose 2 (Table 4), illustrating the 
induction of intestinal immunity by the first dose of mOPV2. 
When calculated among those with any postdose shedding, the 
SIEs were 4.32 and 2.06 after doses 1 and 2, respectively, reinfor-
cing the observation of induced intestinal activity.
All 93 children whose stool samples were evaluated for mucosal 
































Figure 1. Flow chart of the study.
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of the 92 children who shed after the first challenge dose, 67 (73%; 
95% CI, 63%–82%) were observed to achieve a titer ≥8.25 log10 
CCID50 (ie, the ULOQ) in ≥1 sample. Similarly, of the 32 children 
who shed after the second challenge dose 20 (63%; 95% CI, 44%–
79%) reached a titer ≥8.25 log10 CCID50 in ≥1 sample. Individuals 
who shed vaccine virus at the maximum titer after the first dose 
were >5 times more likely to shed at the maximum titer after the 
second dose (odds ratio 5.7; 95% CI, 1.3–24.1).
Intestinal Antibody Responses
Polio type 2–specific IgA concentrations and intestinal neu-
tralizing activity were evaluated in 352 stool samples from 93 
children (median age, 3.4  years; interquartile range, 2.8–4.5), 
in 47 children after 1 mOPV2 challenge dose and in 46 after 2 
doses (Supplementary Tables 1 and 2).
IgA was detected in all stool samples tested. The median 
total IgA concentration in the first stool sample evaluated 
per child was 6.39 μg/mL (interquartile range, 1.87–12.86 μg/
mL). Overall, there was a high degree of concordance between 
presence of poliovirus type 2 specific stool IgA, neutralizing 
activity, and diminished shedding. Two weeks after the first 
mOPV2 dose, there was a strong correlation between polio-
virus type 2–specific stool IgA and neutralizing titer (groups 1 
and 2, Spearman ρ = 0.90; P < .001), and both were negatively 
correlated with mOPV2 shedding (groups 1 and 2, Spearman 
ρ = −0.48 for IgA and shedding and −0.47 for neutralizing titer 
and shedding; both P = .003) (Supplementary Figure 1).
Overall, the intestinal antibody responses to mOPV2 chal-
lenge were lower than expected (Supplementary Figure 2). Of 
children with post–dose 1 mucosal antibody responses 28 of 87 
(32%; 95% CI, 23%–43%) achieved type 2–specific stool neu-
tralizing titers ≥32 after the first mOPV2 dose. Similarly, 16 
of 45 (36%; 95% CI, 22%–51%) with post–dose 2 antibody re-
sponses evaluated had titers ≥32; 5 children who did not re-
spond to the first dose had titers ≥32 after the second, and 2 





(n = 50) Total
Sex, No. (%)    
 Male 24 31 55
 Female 26 19 45
Age, mean (SD), y 3.2 (1.3) 2.8 (1.3) 3.0 (1.3)
Height, mean (SD), cm 100.3 (11.0) 98.1 (11.6) 99.2 (11.3)
Weight, mean (SD), kg 15.8 (3.1) 15.6 (3.1) 15.7 (3.0)
No. of prior IPVs, No (%)    
 3 8 (16) 10 (20) 18 (18)
 4+ 42 (84) 40 (80) 82 (82)
Time since last poliovirus 
vaccination, No. (%)
   
 ≥1 y 43 (86) 36 (72) 79 (79)
 <1 y 7 (14) 14 (28) 21 (21)
Time since last poliovirus 
vaccination for those  
vaccinated <1 y earlier,  
mean (SD), mo
6.4 (2.5) 7.2 (2.7) 6.9 (2.6)
Abbreviations: IPV, inactivated poliovirus vaccine; SD, standard deviation.
Table 2.  Safety Assessment: Solicited and Unsolicited Adverse Eventsa 
Adverse Events
Reports, No. (%)
After Dose 1 (Both   
Groups; N = 100)
After Dose 2  
(Group 2; n = 47)
Any solicited 2 (0) 2 (4)
 Fever 1 (1) 0
 Abnormal crying 1 (1) 0
 Loss of appetite 1 (1) 0
 Irritability 1 (1) 1 (2)
 Vomiting 0 1 (2)
Any unsolicited 14 (14) 4 (9)
 Mild 10 (10) 3 (6)
 Moderate 4 (4) 3 (6)
 Severe 0 0
Leading to withdrawal 0 0
aSolicited adverse events in the 7 days after vaccination and unsolicited adverse events 
throughout the study period. All solicited events were considered mild, and all events were 
considered inconsistent with a causal association to immunization.
Table 3.  Seroprotection and Seroconversion Rates for the 3 Poliovirus Types after 1 Dose in Combined Groups 1 and 2 and After 2 Doses in Group 2 (Per-
Protocol Population)
Rate Day
Seroprotection or Seroconversion Rate, No./Total (%; 95% CI)
Poliovirus Type 1 Poliovirus Type 2 Poliovirus Type 3
Groups 1 and 2 Group 2 Groups 1 and 2 Group 2 Groups 1 and 2 Group 2
Seroprotection 0 93/96 (97; 91.1–99.4) 47/47 (100; 92.5–100) 94/96 (98; 92.7–99.7) 47/47 (100; 92.5–100) 92/96 (96; 89.7–98.9) 45/47 (96; 85.5–99.5) 
7 48/50 (96; 86.3–99.5) … 49/50 (98; 89.4–99.9) … 49/50 (98; 89.4–99.9) …
28 88/90 (98; 92.2–99.7) 45/46 (98; 88.5–99.9) 90/90 (100; 96.0–100) 46/46 (100; 92.3–100) 87/90 (97; 90.6–99.3) 44/46 (96; 85.2–99.5) 
56 … 43/43 (100; 91.8–100) … 43/42 (100; 91.8–100) … 41/43 (95; 84.2–99.4) 
Seroconversiona 7 4/20 (20; 5.7–43.7) … 9/24 (38; 18.8–59.4) … 2/19 (11; 1.3–33.1) …
28 9/29 (31; 15.3–50.8) … 29/41 (71; 54.5–83.9) … 3/31 (10; 2.0–25.8) …
56 … 3/10 (30; 6.7–65.2) … 11/17 (65; 38.3–85.8) … 1/12 (8; 0.2–38.5) 
Abbreviation: CI, confidence interval.
aSeroconversion was calculated only for those whose baseline titer was sufficiently low to allow observation of 4-fold increase without exceeding the upper limit of quantitation (ie, base-
line titer ≤8.5 log2.)
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children with titers ≥32 after the first dose had titers <32 after 
the second. In total, 57 of 93 children (61%; 95% CI, 51%–71%) 
evaluated did not achieve an intestinal neutralizing activity titer 
≥32 at any point during follow-up.
DISCUSSION
After global cessation of OPV2 use with the switch from triva-
lent to bivalent OPV in May 2016, the only source of immunity 
against type 2 polioviruses is from IPV with WHO recom-
mendations to transition to IPV-only schedules when all OPV 
use has ceased to maintain eradication of all types of polio-
viruses [16]. Therefore, understanding the impact of IPV-only 
infant primary schedules on humoral and intestinal protection 
against polio is critical to inform policy decisions on options 
for future outbreak response and preparations for eventual 
cessation of all OPV use. The situation in Lithuania immedi-
ately before the switch, with a 3-dose infant primary series of 
diphtheria and tetanus toxoids and acellular pertussis–hepatitis 
B virus–IPV/H. influenzae type b vaccine and no OPV use in 
routine immunization or supplementary immunization activ-
ities, provided us with a unique opportunity to evaluate intes-
tinal immunogenicity against type 2 in children vaccinated with 
IPV only after challenge doses of mOPV2. This setting closely 
reflects the postswitch and postcertification situation and re-
sponse dynamics to exposure to live type 2 vaccine virus.
A widely accepted surrogate for assessing intestinal mu-
cosal immunity is protection against viral excretion after an 
oral challenge with the live attenuated vaccine [17]. A recent 
review of primary intestinal immunogenicity from sched-
ules using IPV as the only source of type 2 poliovirus vaccine 
found that the majority of vaccinees across most studies shed 
type 2 virus in stool (60.3%–80.5%) after mOPV2 challenge, 
similar to prior experience in IPV-only vaccinated subjects 
receiving an OPV challenge [18]. Interestingly, this review 
found a marginally favorable impact of 2 IPV doses on both 
the proportion of participants shedding virus and the overall 
magnitude of shedding 21 and 28 days after challenge, com-
pared with 1-dose IPV recipients, suggesting some effect of 
IPV on intestinal immunity. The clinical and epidemiologic 
relevance of this impact is not known. More recently, the 
impact of IPV and bivalent OPV on primary intestinal im-
munity has been assessed by measuring poliovirus-specific 
antibodies in stool samples obtained from subjects enrolled 
in randomized controlled trials [11, 19]. These novel assays 
confirm IPV, both conventional and high dose, has limited 
impact on intestinal mucosal immune responses or on lim-
iting viral shedding on challenge.
Several studies over the past decades have confirmed the 
safety and immunogenicity of mOPV2, currently the vaccine 
of choice for outbreak response for type 2 cVDPVs [20]. The 
administration of 1 or 2 doses of mOPV2 was well tolerated 
and safe in this cohort of 1–5-year-olds, with no SAEs or 
severe AEs associated with the vaccine, an important con-
sideration in the use of mOPV2 in outbreak situations. We 
confirmed that after 3–4 doses of IPV in infancy, children 
had high levels of humoral immunity as NAbs against all 3 
polioviruses, in addition to which there was still a small but 
measurable increase in serum NAbs against type 2 poliovirus 
to achieve a 100% seroprotection rate induced by the first 
challenge dose of mOPV2. Seroprotection rates were uni-
formly high at all study time points, precluding observation 
of changes in this rate, and providing limited ability to eval-
uate seroconversion. A second dose did not elicit any further 
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Figure 2. Geometric mean titers (GMTs) (with 95% confidence intervals) of neu-
tralizing antibodies against the 3 poliovirus serotypes in the 2 study groups after 1 
(red symbols) or 2 (blue symbols) challenge doses of and safety of monovalent type 
2 oral poliovirus vaccine (mOPV2).
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Figure 3. Proportions shedding virus in stool samples over the period after vaccination with monovalent type 2 oral poliovirus vaccine, shown as rate after each dose (with pointwise 
95% confidence intervals as shaded areas). The day of cessation was defined as the last day when virus was detected in stool samples, with all following days being negative.
Table 4.  Type 2 Poliovirus Shedding in Stool Samples From Participants After 1 or 2 Doses of Monovalent Type 2 Oral Poliovirus Vaccine (Per-Protocol 
Population)
Sheddinga Groups 1 and 2 After Dose 1 (n = 97) Group 2 After Dose 2 (n = 47)
Days 7, 14, 21, and 28   
Shedders, No./total (%) 30/31 (97) 11/20 (55)
SIE, median (95% CI), log10 CCID50   
 Overall 4.03 (3.11–4.80) 0.69 (.0–2.06)
 Among shedders 4.32 (3.24–4.84) 2.06 (.70–3.01)
Day 7   
Shedders, No./total (%) 85/92 (92) 20/44 (45)
Median (95% CI), log10 CCID50   
 Overall 5.88 (5.44–6.36) 0 (.0 to ≤2.75)
 Among shedders 5.91 (5.72–6.63) 4.42 (2.91–6.09)
Day 14   
Shedders, No./total (%) 55/62 (89) 13/29 (45)
Median (95% CI), log10 CCID50   
 Overall 5.11 (4.19–5.72) 0 (.0–3.0)
 Among shedders 5.41 (4.59–6.06) 4.69 (3.00 to ≥8.25)
Day 21   
Shedders, No./total (%) 44/66 (67) 10/35 (29)
Median (95% CI), log10 CCID50   
 Overall 2.89 (≤2.75 to 3.63) 0 (.0–.0)
 Among shedders 4.05 (3.17–5.31) 3.02 (≤2.75 to 4.05)
Day 28   
Shedders, No./total (%) 34/68 (50) 9/37 (24)
Median (95% CI), log10 CCID50   
 Overall 1.38 (.0–3.19) 0 (.0–.0)
 Among shedders 4.83 (3.69 to ≥8.25) 3.16 (2.78 to ≥8.25)
Abbreviations: CI, confidence interval; SIE, shedding index end point.
aRate and extent of viral shedding in polymerase chain reaction–positive participants. The allowable window for stool samples to contribute to the SIE computation was ±2 days from the 
nominal sampling day.
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immunogenicity has been evaluated in naive infants, a clear 
dose response has been observed with high rates of second-
dose seroconversion [21, 22].
When stool samples were assessed by PCR most children 
had detectable type 2 virus 7  days after exposure to a single 
vaccine dose of mOPV2, the proportion declining slowly 
through 28  days after exposure, when half the children were 
still shedding. Furthermore, 68% of subjects contributing a 
postvaccination sample were shedding ≥8.25 log10 CCID50/g 
of virus within the first 2 weeks after vaccination. Proportions 
shedding and amounts of shed virus were lower after a second 
dose of mOPV2, with 24% of children still shedding 28  days 
later. This indicates that although children had very limited, 
if any, intestinal immunity from an IPV-only infant immuni-
zation schedule, the first mOPV2 vaccination induced some 
measure of intestinal immunogenicity such that shedding de-
creased after a second dose of mOPV2. However, the extent of 
mucosal immunity measured by antibody responses induced by 
the second dose of mOPV2, at 32%, was relatively poor com-
pared with findings in previous studies where mOPV2 was used 
as a challenge vaccine in IPV-immunized infants [8]. 
In the current study, as in others, there was a strong correla-
tion between intestinal poliovirus-specific IgA and neutraliza-
tion. A study in young Swedish adults who had received IPV in 
infancy and were challenged with oral monovalent polio type 
1 found that they had an even more limited intestinal immune 
response [23]. The immunologic mechanisms underlying this 
immune blockade are under active investigation. The current 
study from Lithuania contributes to our understanding of the 
limited protection IPV provides against virus shedding after ex-
posure to live virus, reiterating that IPV may not limit child-to-
child transmission of circulating wild or VDPVs.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
Notes
Acknowledgments. The authors thank all the parents and 
guardians of the participants in the study, the study staff at the 
clinics in Lithuania, and Cassidy L. Papia and Joshua A. Weiner, 
who performed the mucosal immunoglobulin A  analysis. We 
acknowledge the assistance of Keith Veitch (keithveitch com-
munications) for preparing drafts of the manuscript and pro-
viding editorial assistance during the submission.
Disclaimer. The findings and conclusions in this report are 
those of the author(s) and do not necessarily represent the offi-
cial position of the Centers for Disease Control and Prevention 
or other contributing agencies.
Financial support. This study was sponsored by the Fighting 
Infectious Diseases in Emerging Countries (FIDEC) corpora-
tion. Grant funding was provided by the Bill & Melinda Gates 
Foundation. 
Potential conflicts of interest. A. S. B. is a salaried employee, 
and C. G. and R. C. are paid consultants of the Bill & Melinda 
Gates Foundation, which financed the study. R. R. is a salaried 
employee of FIDEC, the study sponsor. All other authors report 
no potential conflicts, other than grant payments to their re-
spective institutions for performing the work. All authors have 
submitted the ICMJE Form for Disclosure of Potential Conflicts 
of Interest. Conflicts that the editors consider relevant to the 
content of the manuscript have been disclosed.
This information has not been presented previously.
References
1. Global Polio Eradication Initiative. Polio this week as of 28 
April 2020. http://polioeradication.org/polio-today/polio-
now/this-week/. Accessed 7 May 2020.
2. Global Polio Eradication Initiative. Global eradication of 
wild poliovirus type 2 declared. http://polioeradication.org/
news-post/global-eradication-of-wild-poliovirus-type-2-
declared/. Accessed 7 May 2020.
3. World Health Organization. Two out of three wild polio-
virus strains eradicated. https://www.who.int/news-room/
feature-stories/detail/two-out-of-three-wild-poliovirus-
strains-eradicated. Accessed 7 May 2020.
4. Jorba J, Diop OM, Iber J, et al. Update on vaccine-derived 
poliovirus outbreaks—worldwide, July 2019–February 
2020. MMWR Morb Mortal Wkly Rep 2020; 69:489–95.
5. Hampton  LM, Farrell  M, Ramirez-Gonzalez  A, et  al; 
Immunization Systems Management Group of the Global 
Polio Eradication Initiative. Cessation of trivalent oral po-
liovirus vaccine and introduction of inactivated poliovirus 
vaccine–worldwide, 2016. MMWR Morb Mortal Wkly Rep 
2016; 65:934–8.
6. Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio 
vaccination: past, present and future. Future Microbiol 
2015; 10:791–808.
7. Hird  TR, Grassly  NC. Systematic review of mucosal im-
munity induced by oral and inactivated poliovirus vaccines 
against virus shedding following oral poliovirus challenge. 
PLoS Pathog 2012; 8:e1002599.
8. Brickley EB, Wieland-Alter W, Connor RI, et al. Intestinal 
immunity to poliovirus following sequential trivalent inacti-
vated polio vaccine/bivalent oral polio vaccine and trivalent 
inactivated polio vaccine-only immunization schedules: 
analysis of an open-label, randomized, controlled trial in 
Chilean infants. Clin Infect Dis 2018; 67:42–50.
9. Van Damme P, De Coster I, Bandyopadhyay AS, et al. The 
safety and immunogenicity of two novel live attenuated 
Intestinal Immunity In IPV-Immunized Children • jid 2021:223 (1 january) • 127
monovalent (serotype 2) oral poliovirus vaccines in healthy 
adults: a double-blind, single-centre phase 1 study. Lancet 
2019; 394:148–58.
10. Kilpatrick DR, Yang CF, Ching K, et al. Rapid group-, se-
rotype-, and vaccine strain-specific identification of polio-
virus isolates by real-time reverse transcription-PCR using 
degenerate primers and probes containing deoxyinosine 
residues. J Clin Microbiol 2009; 47:1939–41.
11. Wright PF, Connor RI, Wieland-Alter WF, et  al. Vaccine-
induced mucosal immunity to poliovirus: analysis of co-
horts from an open-label, randomised controlled trial in 
Latin American infants. Lancet Infect Dis 2016; 16:1377–84.
12. Weldon  WC, Oberste  MS, Pallansch  MA. Standardized 
methods for detection of poliovirus antibodies. Methods 
Mol Biol 2016; 1387:145–76.
13. Gerloff  N, Sun  H, Mandelbaum  M, et  al. Diagnostic assay 
development for polio eradication. J Clin Microbiol 2018; 
56:e01624-17
14. Arita M, Iwai M, Wakita T, Shimizu H. Development of a 
poliovirus neutralization test with poliovirus pseudovirus 
for measurement of neutralizing antibody titer in human 
serum. Clin Vaccine Immunol 2011; 18:1889–94.
15. Wright PF, Wieland-Alter W, Ilyushina NA, et al. Intestinal 
immunity is a determinant of clearance of poliovirus after 
oral vaccination. J Infect Dis 2014; 209:1628–34.
16. World Health Organization. Summary of the April 2017 
meeting of the strategic advisory group of experts on im-
munization. https://www.who.int/immunization/sage/
meetings/2017/april/SAGE_April_2017_Meeting_Web_
summary.pdf. Accessed 7 May 2020.
17. Parker EPK, Grassly NC. Unravelling mucosal immunity to 
poliovirus. Lancet Infect Dis 2016; 16:1310–1.
18. Bandyopadhyay  AS, Modlin  JF, Wenger  J, Gast  C. 
Immunogenicity of new primary immunization schedules 
with inactivated poliovirus vaccine and bivalent oral polio 
vaccine for the polio endgame: a review. Clin Infect Dis 
2018; 67:35–41.
19. Brickley EB, Strauch CB, Wieland-Alter WF, et al. Intestinal 
immune responses to type 2 oral polio vaccine (OPV) chal-
lenge in infants previously immunized with bivalent OPV 
and either high-dose or standard inactivated polio vaccine. 
J Infect Dis 2018; 217:371–80.
20. Cáceres  VM, Sutter  RW. Sabin monovalent oral polio 
vaccines: review of past experiences and their poten-
tial use after polio eradication. Clin Infect Dis 2001; 
33:531–41.
21. Sutter  RW, John  TJ, Jain  H, et  al. Immunogenicity of 
bivalent types 1 and 3 oral poliovirus vaccine: a ran-
domised, double-blind, controlled trial. Lancet 2010; 
376:1682–8.
22. Zaman K, Estívariz CF, Morales M, et al. Immunogenicity 
of type 2 monovalent oral and inactivated poliovirus vac-
cines for type 2 poliovirus outbreak response: an open-
label, randomised controlled trial. Lancet Infect Dis 2018; 
18:657–65.
23. Brickley EB, Connor RI, Wieland-Alter WF, et al. Intestinal 
antibody responses to a live oral poliovirus vaccine chal-
lenge among adults previously immunized with inacti-
vated polio vaccine in Sweden. BMJ Glob Health 2019; 
4:e001613.
